Arcus Biosciences Inc (RCUS)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -282,000 | -301,000 | -266,000 | 55,000 | -156,800 |
| Revenue | US$ in thousands | 258,000 | 117,000 | 112,000 | 382,882 | 77,517 |
| Pretax margin | -109.30% | -257.26% | -237.50% | 14.36% | -202.28% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $-282,000K ÷ $258,000K
= -109.30%
The pretax margin of Arcus Biosciences Inc has experienced significant fluctuations over the past years. In 2020, the company reported a negative pretax margin of -202.28%, indicating that its expenses exceeded its revenues before accounting for taxes. However, in 2021, Arcus Biosciences Inc showed improvement with a pretax margin of 14.36%, reflecting better cost management and profitability.
Subsequently, the pretax margin deteriorated sharply in 2022 and 2023, with figures of -237.50% and -257.26% respectively, suggesting severe financial challenges and potentially unsustainable business operations.
Nevertheless, there was a partial recovery in 2024 as the pretax margin improved to -109.30%, indicating some progress in controlling costs and increasing operational efficiency. Overall, the company's pretax margin has been volatile, highlighting the importance of closely monitoring and addressing its financial performance and profitability levels.
Peer comparison
Dec 31, 2024